Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / KPTI - KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI


KPTI - KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI).

On February 22, 2019, the Federal Drug Administration ("FDA") reported serious flaws in the New Drug Application and the underlying clinical trial data for the Company’s drug, selinexor. Specifically, the FDA detailed that the Company’s clinical trials demonstrated a history of toxicity and limited efficacy findings due to its trial designs and faulted the Company for violating pre-specified trial protocols and guidance when attempting to use “real-world” data observations to bolster its case for approval.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether Karyopharm’s officers and/or directors breached their fiduciary duties to Karyopharm’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Karyopharm shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ( lewis.kahn@ksfcounsel.com ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-kpti/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005742/en/

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Stock Information

Company Name: Karyopharm Therapeutics Inc.
Stock Symbol: KPTI
Market: NASDAQ
Website: karyopharm.com

Menu

KPTI KPTI Quote KPTI Short KPTI News KPTI Articles KPTI Message Board
Get KPTI Alerts

News, Short Squeeze, Breakout and More Instantly...